NEO Looks 8.2% Overvalued on GF Value™

gurufocus.com · 2026-08-26

On August 26, 2026, NeoGenomics Inc (NASDAQ: NEO) announced a major expansion in Medicare coverage for its RaDaR ST molecular residual disease assay, now includ

Read the full story at gurufocus.com →